Fonte: Brazilian Journal of Pharmaceutical Sciences. Nome do evento: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo. Unidades: FCF, ICB
Assuntos: MYCOBACTERIUM TUBERCULOSIS, INIBIDORES DE ENZIMAS
ABNT
SOUZA, Alfredo Danilo Ferreira de et al. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 18 jun. 2024. , 2018APA
Souza, A. D. F. de, Ribeiro, J. A., Ribeiro, G. M., Trossini, G. H. G., Dias, M. V. B., & Parise Filho, R. (2018). Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Souza ADF de, Ribeiro JA, Ribeiro GM, Trossini GHG, Dias MVB, Parise Filho R. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 39 res. FCF073.[citado 2024 jun. 18 ]Vancouver
Souza ADF de, Ribeiro JA, Ribeiro GM, Trossini GHG, Dias MVB, Parise Filho R. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 39 res. FCF073.[citado 2024 jun. 18 ]